ENHANCE trial: adherence to current antipsychotic and adjunctive pimavanserin in patients with schizophrenia and inadequate response to antipsychotic treatment

Category Primary study
JournalEUROPEAN NEUROPSYCHOPHARMACOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 80266179d9d79e5afe99b9ac57a845c93d6c48a2
First added on: Feb 12, 2025